StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
47
This year
2
Publishing Date
2024 - 03 - 15
1
2024 - 03 - 11
1
2023 - 12 - 18
1
2023 - 11 - 10
1
2023 - 10 - 26
1
2023 - 09 - 11
1
2023 - 06 - 05
1
2023 - 06 - 01
1
2023 - 04 - 07
1
2023 - 03 - 06
2
2023 - 03 - 01
1
2023 - 02 - 22
1
2023 - 02 - 16
1
2023 - 02 - 03
1
2023 - 02 - 02
1
2023 - 01 - 25
2
2022 - 12 - 12
1
2022 - 11 - 22
1
2022 - 10 - 18
1
2022 - 09 - 22
1
2022 - 06 - 29
1
2022 - 06 - 21
1
2022 - 06 - 07
1
2022 - 05 - 05
1
2022 - 05 - 04
1
2022 - 03 - 22
1
2022 - 02 - 23
1
2022 - 02 - 14
1
2022 - 02 - 01
1
2022 - 01 - 05
1
2021 - 11 - 22
1
2021 - 11 - 17
1
2021 - 11 - 11
1
2021 - 10 - 15
1
2021 - 08 - 25
1
2021 - 07 - 21
1
2021 - 07 - 01
1
2021 - 06 - 03
1
2021 - 06 - 01
1
2021 - 03 - 08
1
2021 - 03 - 02
1
2021 - 02 - 01
1
2021 - 01 - 26
1
2021 - 01 - 08
1
2020 - 12 - 23
1
Sector
Communications
2
Health technology
47
Manufacturing
1
Tags
Alliances
17
Antiviral
14
Application
11
Approval
8
Breast cancer
7
Canada
6
Cancer
75
Cell
14
Cell carcinoma
10
Children
7
Chmp
12
Clinical-trials-phase-ii
9
Clinical-trials-phase-iii
41
Conference
33
Covid
21
Covid-19
10
Disease
12
Drug
6
Earnings
21
Europe
8
Events
28
Fda
36
Fda approval
8
Fda-approvals
12
Financial
6
Financial results
6
Health
13
Her2
8
Her2-
7
Hiv
12
Infections
6
Ipo
6
Keytruda
84
License
9
Lung
11
Lynparza
11
Merck
50
Molnupiravir
19
N/a
22
People
13
Pharm-country
47
Pharmaceutical
34
Phase 3
18
Plus
30
Pneumococcal
12
Positive
19
Product-news
9
Prostate cancer
10
Regulatory
27
Renal
12
Research
30
Results
28
Risk
12
Sales
11
Therapy
31
Treatment
63
Trial
45
Trials
8
Update
15
Vaccine
20
Entities
Abbvie inc.
1
Astellas pharma inc
1
Harpoon therapeutics, inc.
1
Imago biosciences inc
1
Merck & company, inc.
47
Moderna, inc.
3
Orange
2
Sanofi
3
Seagen inc.
1
Symbols
AMRN
14
AMRX
26
ANVS
16
APDN
36
ATNM
19
AVXL
12
BDX
20
BHVN
16
BMY
67
CERT
12
CTSO
12
CTXR
16
DGX
21
ECOR
19
FNCTF
22
HOTH
19
HSIC
14
ICPT
12
IMUX
15
INAB
17
INSM
21
ISEE
14
JNJ
71
KRMD
18
KRYS
12
LEGN
20
LLY
15
LUCD
17
MRK
47
MRNS
23
MS
15
NAOV
14
NRXP
21
ORMP
15
PAVM
17
PDSB
20
PFE
34
PTCT
14
PTPI
16
RCKT
15
REGN
13
RLYB
13
SCYX
12
SDGR
22
SEEL
18
SLS
16
SNGX
20
SNY
55
SNYNF
43
SONN
14
STIM
16
TEVA
19
TEVJF
18
TGTX
14
TNXP
31
TRVI
12
TRVN
16
URGN
25
VRPX
17
YMAB
22
Exchanges
Nasdaq
8
Nyse
47
Crawled Date
2024 - 03 - 15
1
2024 - 03 - 11
1
2023 - 12 - 18
1
2023 - 11 - 10
1
2023 - 10 - 26
1
2023 - 09 - 11
1
2023 - 06 - 05
1
2023 - 06 - 01
1
2023 - 04 - 07
1
2023 - 03 - 06
2
2023 - 03 - 01
1
2023 - 02 - 22
1
2023 - 02 - 16
1
2023 - 02 - 03
1
2023 - 02 - 02
1
2023 - 01 - 25
2
2022 - 12 - 12
1
2022 - 11 - 22
1
2022 - 10 - 18
1
2022 - 09 - 22
1
2022 - 06 - 29
1
2022 - 06 - 21
1
2022 - 06 - 07
1
2022 - 05 - 05
1
2022 - 05 - 04
1
2022 - 03 - 22
1
2022 - 02 - 23
1
2022 - 02 - 14
1
2022 - 02 - 01
1
2022 - 01 - 05
1
2021 - 11 - 22
1
2021 - 11 - 17
1
2021 - 11 - 11
1
2021 - 10 - 15
1
2021 - 08 - 25
1
2021 - 07 - 21
1
2021 - 07 - 01
1
2021 - 06 - 03
1
2021 - 06 - 01
1
2021 - 03 - 08
1
2021 - 03 - 02
1
2021 - 02 - 01
1
2021 - 01 - 26
1
2021 - 01 - 08
1
2020 - 12 - 23
1
Crawled Time
11:00
8
12:00
10
12:15
1
12:20
3
12:30
3
13:00
5
14:00
4
14:20
1
15:00
2
16:00
3
18:00
2
19:00
1
19:01
1
21:00
3
Source
www.biospace.com
47
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Pharm-country
symbols :
Mrk
save search
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Published:
2024-03-15
(Crawled : 11:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
5.34%
|
O:
-0.56%
H:
1.75%
C:
1.4%
keytruda
cancer
alone
advanced
plus
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Published:
2024-03-11
(Crawled : 16:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
2.79%
|
O:
0.93%
H:
0.0%
C:
-1.51%
merck
acquisition
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors
Published:
2023-12-18
(Crawled : 14:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
20.77%
|
O:
1.0%
H:
0.99%
C:
-0.11%
keytruda
tumors
advanced
plus
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published:
2023-11-10
(Crawled : 14:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
23.99%
|
O:
0.45%
H:
0.51%
C:
-1.41%
keytruda
chmp
merck
positive
cancer
treatment
plus
gemcitabine
Merck Announces Third-Quarter 2023 Financial Results
Published:
2023-10-26
(Crawled : 11:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
22.49%
|
O:
-0.51%
H:
4.0%
C:
2.38%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-12.84%
|
O:
0.09%
H:
0.0%
C:
0.0%
MRNA
|
News
S
|
$107.87
3.26%
3.16%
2.4M
|
Health Technology
|
36.09%
|
O:
-0.04%
H:
0.64%
C:
-0.98%
merck
financial
results
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Published:
2023-09-11
(Crawled : 12:30)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
16.41%
|
O:
0.25%
H:
0.11%
C:
-0.66%
merck
hypertension
potential
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)
Published:
2023-06-05
(Crawled : 13:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
12.82%
|
O:
0.43%
H:
1.31%
C:
0.1%
MRNA
|
News
S
|
$107.87
3.26%
3.16%
2.4M
|
Health Technology
|
-19.96%
|
O:
0.38%
H:
2.74%
C:
-1.6%
rna-4157
merck
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published:
2023-06-01
(Crawled : 12:20)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
14.97%
|
O:
0.23%
H:
0.84%
C:
0.24%
lynparza
fda
cancer
treatment
plus
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
Published:
2023-04-07
(Crawled : 12:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
Email alert
Add to watchlist
leap-003
keytruda
melanoma
merck
update
cancer
trials
plus
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
Published:
2023-03-06
(Crawled : 21:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
18.77%
|
O:
0.73%
H:
3.33%
C:
3.2%
hypertension
week
therapy
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
Published:
2023-03-06
(Crawled : 21:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
18.77%
|
O:
0.73%
H:
3.33%
C:
3.2%
mk-0616
study
hypercholesterolemia
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
Published:
2023-03-01
(Crawled : 12:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
19.48%
|
O:
-0.26%
H:
1.5%
C:
0.65%
ynote-671
lung
trial
cancer
Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
Published:
2023-02-22
(Crawled : 13:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
16.38%
|
O:
1.05%
H:
0.1%
C:
-0.95%
treatment
trials
infection
hiv
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
Published:
2023-02-16
(Crawled : 18:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
17.89%
|
O:
-0.8%
H:
0.6%
C:
-0.29%
keytruda
plus
her2
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Published:
2023-02-03
(Crawled : 14:20)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
22.69%
|
O:
-0.23%
H:
0.55%
C:
-0.27%
keytruda
plus
therapy
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
Published:
2023-02-02
(Crawled : 14:00)
- biospace.com/
ALPMY
|
News
|
$9.53
-1.11%
690K
|
Manufacturing
|
-35.39%
|
O:
1.22%
H:
0.0%
C:
-1.61%
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
18.66%
|
O:
-2.77%
H:
1.72%
C:
-0.54%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
64.53%
|
O:
-0.37%
H:
1.07%
C:
0.66%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-4.69%
|
O:
-1.44%
H:
0.0%
C:
0.0%
MRNA
|
News
S
|
$107.87
3.26%
3.16%
2.4M
|
Health Technology
|
-40.07%
|
O:
-0.52%
H:
1.92%
C:
1.7%
financial
results
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
Published:
2023-01-25
(Crawled : 12:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
16.97%
|
O:
0.18%
H:
1.12%
C:
-0.11%
ynote-966
keytruda
trial
plus
cancer
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
Published:
2023-01-25
(Crawled : 12:00)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
16.97%
|
O:
0.18%
H:
1.12%
C:
-0.11%
ynote-991
keytruda
trial
plus
therapy
cancer
prostate cancer
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
Published:
2022-12-12
(Crawled : 12:00)
- biospace.com/
IMGO
|
$36.01
0.03%
0.0%
0
|
Health Technology
|
0.32%
|
O:
0.01%
H:
0.15%
C:
-0.11%
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
16.69%
|
O:
-0.78%
H:
1.08%
C:
0.96%
acquire
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Published:
2022-11-22
(Crawled : 12:20)
- biospace.com/
MRK
|
$126.88
-0.05%
-0.13%
7.5M
|
Health Technology
|
20.2%
|
O:
0.49%
H:
0.92%
C:
0.73%
ynote-859
trial
her2-
her2
← Previous
1
2
3
Next →
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.